LDE225

Phase 1Completed

0 views this week 0 watching💤 Quiet

Interest: 29/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Normal Hepatic Function

Conditions

Normal Hepatic Function, Impaired Hepatic Function

Trial Timeline

Mar 1, 2013 → Mar 1, 2015

NCT ID

NCT01764776

About LDE225

LDE225 is a phase 1 stage product being developed by Novartis for Normal Hepatic Function. The current trial status is completed. This product is registered under clinical trial identifier NCT01764776. Target conditions include Normal Hepatic Function, Impaired Hepatic Function.

What happened to similar drugs?

4 of 6 similar drugs in Normal Hepatic Function were approved

Approved (4) Terminated (2) Active (2)

✅DonepezilEisaiApproved

✅Eybelis ophthalmic solution 0.002%Santen PharmaceuticalApproved

✅cyclosporine micro-emulsionNovartisApproved

✅Aspirin 100 mg + PlaceboBayerApproved

🔄Gadopentetate dimeglumine (Magnevist)BayerPhase 3

🔄lixivaptan + placeboBiogenPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (11)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02195973	Phase 1	Completed	Sep 1, 2014	Sep 30, 2017	Recurrent Ovarian Cancer
NCT02151864	Phase 1	Completed	Jul 1, 2014	Sep 1, 2017	Hepatocellular Carcinoma
NCT02086513	Phase 1	Terminated	Apr 1, 2014	Dec 1, 2016	Graft Versus Host Disease
NCT02002689	Phase 2	Terminated	Feb 1, 2014	Mar 1, 2015	PTCH1 or SMO Activated Solid and Hematologic Tumors
NCT01826214	Phase 2	Completed	May 1, 2013	May 1, 2015	Acute Leukemias
NCT01764776	Phase 1	Completed	Mar 1, 2013	Mar 1, 2015	Normal Hepatic Function
NCT01529450	Pre-clinical	Completed	Feb 1, 2012	Aug 1, 2013	Basal Cell Carcinoma
NCT01327053	Phase 2	Completed	Jun 29, 2011	Jun 29, 2018	Basal Cell Carcinoma
NCT01125800	Phase 1/2	Completed	Feb 1, 2011	Oct 1, 2014	Medulloblastoma
NCT01208831	Phase 1	Completed	Oct 1, 2010	Oct 1, 2013	Advanced Solid Tumor Cancers
NCT00880308	Phase 1	Completed	Mar 1, 2009	Jul 1, 2013	Advanced Solid Tumor Cancers

Competing Products

20 competing products in Normal Hepatic Function

See all competitors

Product	Company	Stage	Hype Score
Roxadustat	Astellas Pharma	Phase 1	29
Donepezil	Eisai	Approved	43
eribulin mesylate	Eisai	Phase 2	35
Lurasidone HCl	Sumitomo Pharma	Phase 1	29
Eybelis ophthalmic solution 0.002%	Santen Pharmaceutical	Approved	39
Triptorelin	Merck	Pre-clinical	26
Temozolomide + Vorinostat	Merck	Phase 2	35
LDK378	Novartis	Phase 1	29
cyclosporine micro-emulsion	Novartis	Approved	35
LDK378	Novartis	Phase 1	29
LEE011	Novartis	Phase 1	29
LEE011	Novartis	Phase 1	29
mycophenolate mofetil	Roche	Phase 1	29
filgrastim	Amgen	Pre-clinical	26
PF-06423264	Pfizer	Phase 1	21
PF-05221304	Pfizer	Phase 1	29
BMS-933043 + Placebo matching with BMS-933043 + Antacid Buffer Predose Solution	Bristol Myers Squibb	Phase 1	29
tolebrutinib	Sanofi	Phase 1	29
Venglustat (GZ402671)	Sanofi	Phase 1	29
Rilzabrutinib	Sanofi	Phase 1	29